Vascular dementia - Diagnosis, prevention and treatment;Vaskuläre demenzen - Diagnostik, prävention und therapie

Psychiatrische Praxis

Volumn 31, Issue 7, 2004, Pages 330-338

  Wolf, Henrike ^a,c   Gertz, Hermann Josef ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN; CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE; NIMODIPINE; NOOTROPIC AGENT; PIRACETAM; RIVASTIGMINE;

AGED; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; HUMAN; INCIDENCE; MULTIINFARCT DEMENTIA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 7544233863     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828378     Document Type: Review

References (59)

1. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-S15
2. Statistisches Bundesamt. Gesundheitsbericht für Deutschland. Stuttgart: Metzler-Poeschel, 1998
3. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke 1997; 28: 729-735
4. Vermeer SE, Prins ND, Heijer T den, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222
5. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817
6. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999; 354: 919-920
7. Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry 2000; 15: 803-812
8. Torre JC de la. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152-1162
9. Alzheimer A. Die Seelenstörungen auf arteriosklerotischer Grundlage. Allg Z Psychiat 1902; 59: 695-711
10. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Clinical features of MRI-defined subcortical vascular disease. Alzheimer Dis Assoc Disord 2003; 17: 236-242
11. Nissl F. Zur Kasuisitik der arteriosklerotischen Demenz (Ein Fall von sogenannter "Encephalitis subcorticalis"). Z ges Neurol Psychiat 1920; 19: 438-443
12. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426-436
13. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260
14. th. Washington D. C.: American Psychiatric Press, 1994
15. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473-480
16. World Health Organisation. International Classification of Diseases, ed. 10. Geneva: 1990
17. Binswanger O. Die Abgrenzung der allgemeinen progressiven Paralyse (Referat erstattet auf der Jahresversammlung des Vereins deutscher Irrenärzte zu Dresden am 20. September 1804). Berl klin Wschr 1894; 31: 1103-1105, 1137-1139, 1180-1189
18. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23-30
19. Pasquier F. Early diagnosis of dementia: neuropsychology. J Neurol 1999; 246: 6-15
20. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol 2003; 2: 89-98
21. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-488
22. Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund LO, Gertz HJ. Structural correlates of mild cognitive impairment. Neurobiol Aging 2004; 25: 913-924
23. Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003; 6: 750-757
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319
25. Weih M, Muller-Nordhorn J, Amberger N, Masuhr F, Lurtzing F, Dreier JP, Hetzel A. Risk in ischemic stroke-review of evidence in primary prevention. Nervenarzt 2004; 75: 324-335
26. Leys D, Kwiecinski H, Bogousslavsky J, Bath P, Brainin M, Diener HC, Kaste M, Sivenius J, Hennerici MG, Hacke W. Prevention. European Stroke Initiative. Cerebrovasc Dis 2004; 17, Suppl 2:15-29
27. Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK. Risk factors for incident dementia after stroke. Role of hypoxic and ischemic disorders. Stroke 1996; 27: 1283-1289
28. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052
29. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075
30. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886
31. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2: 23-28
32. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444
33. Piechowski-Jozwiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive? Stroke 2004; 35: 1523-1524
34. Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271-278
35. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20
36. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissien A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451
37. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001; 57: 1447-1452
38. Exel E van, Craen AJM de, Gussekloo J, Houx P, Bootsma-Wiel A van der, Macfarlane PW, Blauw GJ, Westendorp RGJ. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002; 51: 716-721
39. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443
40. Jick H, Zornberg GL, Jack SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631
41. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378-384
42. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767
43. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630
44. Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls? Lancet 2000; 355: 1925-1926
45. Nhan H, Barquist K, Bell K, Esselman P, Odderson IR, Cramer SC. Brain function early after stroke in relation to subsequent recovery. J Cereb Blood Flow Metab 2004; 24: 756-763
46. Gertz HJ, Wolf H, Arendt T. Vaskuläre Demenz (Vascular Dementia). Nervenarzt 2002; 73: 393-404
47. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev, 2002, CD000147
48. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305
49. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-1839
50. Wallin A, Alafuzoff I, Carlsson A, Eckernas SA, Gottfries CG, Karlsson I, Svennerholm L, Winblad B. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 1989; 79: 397-406
51. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330
52. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-486
53. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-1290
54. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003; 18: 265-272
55. Bates J, Boote J, Beverley C. Psychosocial interventions for people with a milder dementing illness: a systematic review. J Adv Nurs 2004; 45: 644-658
56. Kruglov LS. The early stage of vascular dementia: significance of a complete therapeutic program. Int J Geriatr Psychiatry 2003; 18: 402-406
57. Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 2003; 183: 248-254
58. Koch K. MONICA-Projekt. Eine Todesursache ändert ihren Charakter. Deutsches Ärzteblatt 2000; 97: A583-A584
59. Scherpinski U, Bickel H, Gnahn H, Forstl H, Conrad B, Sander D. Intervention project on cerebrovascular diseases and dementia in the Ebersberg district (INVADE): rationale and design. Nervenarzt 2002; 73: 1199-1204